Ascentage Pharma Group International (HKG:6855) reported a net loss attributable to shareholders of 590.8 million yuan for the first half of 2025, compared with a profit of 163.0 million yuan a year earlier.

Loss per share was 1.73 yuan, compared with earnings per share of 0.55 yuan a year earlier.

Revenue fell 71.6% to 233.7 million yuan, compared with 823.7 million yuan in the prior-year period.